Cargando…
Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
Background. The minimal clinically important difference (MCID) is the smallest change in an outcome measure that is meaningful for patients. Objectives. To calculate the MCID for Unified Parkinson's Disease Rating Scale (UPDRS) scores in early Parkinson's disease (EPD) and for UPDRS scores...
Autores principales: | Hauser, Robert A., Gordon, Mark Forrest, Mizuno, Yoshikuni, Poewe, Werner, Barone, Paolo, Schapira, Anthony H., Rascol, Olivier, Debieuvre, Catherine, Fräßdorf, Mandy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995302/ https://www.ncbi.nlm.nih.gov/pubmed/24800101 http://dx.doi.org/10.1155/2014/467131 |
Ejemplares similares
-
Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
por: Hauser, R A, et al.
Publicado: (2014) -
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
por: Schapira, Anthony HV, et al.
Publicado: (2013) -
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012) -
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022) -
Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)